Loading
Glecirasib is Jacobio's KRAS G12C inhibitor, approved in China in 2024 for previously treated non-small cell lung cancer with that mutation, and in a phase 3 trial against docetaxel.
Jacobio Pharma developed glecirasib (JAB-21822) and partnered it with Allist Pharmaceuticals for China. The NMPA approved it in 2024 for KRAS G12C-mutant non-small cell lung cancer after at least one prior systemic therapy, on a single-arm phase 2 trial with a response rate in the range of the approved Western inhibitors and a low rate of gastrointestinal side effects. A randomised phase 3 trial against docetaxel and combination studies with a SHP2 inhibitor are registered.
Binds the mutant cysteine of KRAS G12C and locks the protein in its inactive state, the same mechanism as sotorasib and adagrasib. Connects to KRAS.
1.Glecirasib slips into a pocket on KRAS.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2024 | KRAS G12C-mutant advanced non-small cell lung cancer after prior systemic therapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Glecirasib" OR ABSTRACT:"Glecirasib" OR TITLE:"JAB-21822" OR ABSTRACT:"JAB-21822") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Glecirasib, not a curated reading list.
Shares JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation, Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation, SHP2 (PTPN11), Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag pipeline.
Shares Jacobio Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.